COPY

2600 Hile

## **PATENT**

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

C. P. Dorn, et al.

Serial No.:

08/525,259 - Case No.: 18747ID

Art Unit:

Filed:

September 8, 1995

Examiner:

For:

MORPHOLINE AND THIOMORPHOLINE

TACHYKININ RECEPTOR

**ANTAGONISTS** 

ULL 0 6 199

Honorable Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

<u>INFORMATION DISCLOSURE STATEMENSEP</u> 0 8 1997 <u>UNDER 37 C.F.R. §1.56 AND §1.97</u>

80

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

## **CERTIFICATE OF MAILING**

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISIONER FOR PATENTS WASHINGTON, D.C. 20231

ON THE DATE APPEARING BELOW:

DV. C. Geli OMIN

DATE: 06 DECEMBER 1995





Semi No.: 08/525,2 Case No.: 18747ID

Page 2

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the instant application.

The references on the attached form PTO-1449 were previously submitted to or cited by the Office in prior applications U.S. Serial No. 08/169,889, filed December 17, 1993 (Merck Case No. 18747IC), U.S. Serial No. 08/061,914, filed May 19, 1993 (Merck Case No. 18747IB), U.S. Serial No. 07/971,448, filed November 4, 1992 (Merck Case No. 18747IA) and U.S. Serial No. 07/905,976, filed June 29, 1992 (Merck Case No. 18747), upon which the instant application relies for an earlier filing date under 35 U.S.C. §120.





Sε 1 No.: 08/525,259 Case No.: 18747ID

Page 3

Therefore, pursuant to 37 CFR § 1.98(d), copies of these references are not enclosed herewith. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

J./Eric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., INC.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(908) 594-3904

Date: December 6, 1995



P&I OFFICE ACKNOWLEDGEMENT	
ATTORNEY	DATE
J.E. Thies	12/6/95
CASE NUMBER	EXPRESS
18747ID	MAK SKILES
SERIAL NUMBER	0,0
08/525,259	150
DATE FILED	<b>※ &lt;</b>
9/8/95	
INT. NUMBER	AK OFF.
APPLICANT	
C.P. Dorn et al	
The Patent & Trademark Office acknowledges, and has	
stamped hereon, the date of the receipt of the items checked below:	
T' AFFIDAVIT - UNDER RULE	
AMENDMENT	
APPEAL AND FEE	
☐ ASSIGNMENT	
□ BŘĮEF	
CETIFICATE OF CORRE	CTION
☐ FINAL FEE	
☐ LETTER ☐ REQUEST FOR F.F. LICE	INSE
☐ MOTION	
T INFORMATION DISCLOS	SURE STATEMENT
X PTO 1449 & REFERENCES (previously submitted)	
□ PRELIMINARY STATEM!	ENT
STIPULATION	
☐ PETITION FOR EXTENS	
	F1071